Ana Lucia L Abujamra

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4741017/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Gastrin-releasing peptide receptor (GRPR) mediates chemotaxis in neutrophils. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 547-552.	7.1	61
2	PRIMA-1, a mutant p53 reactivator, induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell lines. Investigational New Drugs, 2014, 32, 783-794.	2.6	55
3	BDNF/TrkB Content and Interaction with Gastrin-Releasing Peptide Receptor Blockade in Colorectal Cancer. Oncology, 2010, 79, 430-439.	1.9	50
4	The Histone Deacetylase Inhibitor Sodium Butyrate Promotes Cell Death and Differentiation and Reduces Neurosphere Formation in Human Medulloblastoma Cells. Molecular Neurobiology, 2013, 48, 533-543.	4.0	48
5	BDNF/TrkB signaling protects HT-29 human colon cancer cells from EGFR inhibition. Biochemical and Biophysical Research Communications, 2012, 425, 328-332.	2.1	41
6	Glioma Revisited: From Neurogenesis and Cancer Stem Cells to the Epigenetic Regulation of the Niche. Journal of Oncology, 2012, 2012, 1-20.	1.3	40
7	Characterization of Ectonucleotidases in Human Medulloblastoma Cell Lines: ecto-5′NT/CD73 in Metastasis as Potential Prognostic Factor. PLoS ONE, 2012, 7, e47468.	2.5	37
8	BDNF and PDE4, but not the GRPR, Regulate Viability of Human Medulloblastoma Cells. Journal of Molecular Neuroscience, 2010, 40, 303-310.	2.3	34
9	BDNF/TrkB signaling as an anti-tumor target. Expert Review of Anticancer Therapy, 2011, 11, 1473-1475.	2.4	32
10	Current and emerging molecular targets in glioma. Expert Review of Anticancer Therapy, 2010, 10, 1735-1751.	2.4	31
11	Targeting Histone Deacetylase Activity to Arrest Cell Growth and Promote Neural Differentiation in Ewing Sarcoma. Molecular Neurobiology, 2018, 55, 7242-7258.	4.0	28
12	Histone deacetylase inhibitors: A new perspective for the treatment of leukemia. Leukemia Research, 2010, 34, 687-695.	0.8	26
13	The use of highâ€frequency audiometry increases the diagnosis of asymptomatic hearing loss in pediatric patients treated with cisplatinâ€based chemotherapy. Pediatric Blood and Cancer, 2013, 60, 474-478.	1.5	26
14	Combined Treatments with a Retinoid Receptor Agonist and Epigenetic Modulators in Human Neuroblastoma Cells. Molecular Neurobiology, 2017, 54, 7610-7619.	4.0	26
15	Sodium butyrate enhances the cytotoxic effect of antineoplastic drugs in human lymphoblastic T-cells. Leukemia Research, 2009, 33, 218-221.	0.8	24
16	In vitro antitumor effect of sodium butyrate and zoledronic acid combined with traditional chemotherapeutic drugs: A paradigm of synergistic molecular targeting in the treatment of Ewing sarcoma. Oncology Reports, 2014, 31, 955-968.	2.6	22
17	Leukemia virus long terminal repeat activates NFκB pathway by a TLR3-dependent mechanism. Virology, 2006, 345, 390-403.	2.4	21
18	Tryptophan hydroxylase 2 (TPH2) gene polymorphisms and psychiatric comorbidities in temporal lobe epilepsy. Epilepsy and Behavior, 2014, 32, 59-63.	1.7	21

Ana Lucia L Abujamra

#	Article	IF	CITATIONS
19	Cancer Stem Cells and the Biology of Brain Tumors. Current Stem Cell Research and Therapy, 2009, 4, 306-313.	1.3	19
20	The histone deacetylase inhibitor sodium butyrate in combination with brain-derived neurotrophic factor reduces the viability of DAOY human medulloblastoma cells. Child's Nervous System, 2011, 27, 897-901.	1.1	18
21	HER2 as a cancer stem-cell target. Lancet Oncology, The, 2010, 11, 225-226.	10.7	17
22	Inhibitory Activities of Trichostatin A in U87 Glioblastoma Cells and Tumorsphere-Derived Cells. Journal of Molecular Neuroscience, 2014, 54, 27-40.	2.3	14
23	A gastrinâ€releasing peptide receptor antagonist stimulates Neuro2a neuroblastoma cell growth: Prevention by a histone deacetylase inhibitor. Cell Biology International, 2009, 33, 899-903.	3.0	13
24	Antiproliferative activity of the dimeric phloroglucinol and benzophenone derivatives of Hypericum spp. native to southern Brazil. Anti-Cancer Drugs, 2013, 24, 699-703.	1.4	13
25	Ewing's sarcoma: Analysis of single nucleotide polymorphism in the EWS gene. Gene, 2012, 509, 263-266.	2.2	12
26	Ewing Sarcoma: influence of TP53 Arg72Pro and MDM2 T309G SNPs. Molecular Biology Reports, 2013, 40, 4929-4934.	2.3	11
27	Effects of Lonomia obliqua caterpillar venom upon the proliferation and viability of cell lines. Cytotechnology, 2014, 66, 63-74.	1.6	11
28	Anti-EGFR therapy combined with neuromedin B receptor blockade induces the death of DAOY medulloblastoma cells. Child's Nervous System, 2013, 29, 2145-2150.	1.1	8
29	Mutations that abrogate transactivational activity of the feline leukemia virus long terminal repeat do not affect virus replication. Virology, 2003, 309, 294-305.	2.4	7
30	TREM2, Frontotemporal Dementia–Like Disease, Nasu-Hakola Disease, and Alzheimer Dementia: A Chicken and Egg Problem?. JAMA Neurology, 2013, 70, 805.	9.0	7
31	Methylation of BDNF and SLC6A4 Gene Promoters in Brazilian Patients With Temporal Lobe Epilepsy Presenting or Not Psychiatric Comorbidities. Frontiers in Integrative Neuroscience, 2021, 15, 764742.	2.1	5
32	Phosphodiesterase-4 Inhibition and Brain Tumor Growth. Clinical Cancer Research, 2009, 15, 3238-3238.	7.0	3
33	Regulation of E adherin expression by growth factor receptors in cancer cells. Journal of Surgical Oncology, 2011, 104, 220-221.	1.7	3
34	Development of an online tool to determine appropriateness for an epilepsy surgery evaluation. Neurology, 2013, 80, 2169-2169.	1.1	2
35	Neutrality of miniSTR D22S1045 marker by Ewing's sarcoma phenotype. Legal Medicine, 2013, 15, 335-337.	1.3	0
36	ReactivationÂof p53 mutant protein by PRIMA-1 and induction of apoptosisÂin pancreatic cancer cells Journal of Clinical Oncology, 2012, 30, e13546-e13546.	1.6	0